文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

黑色素瘤脑转移推荐一线管理:一项多中心临床实践调查

Recommended first-line management of brain metastases from melanoma: A multicenter survey of clinical practice.
PubMed 文献 · Radiother Oncol · 2022-02-02

该国际调查向肿瘤内科、临床肿瘤科、放射肿瘤科和神经外科专家呈现18个无症状BRAF突变阳性或阴性黑色素瘤脑转移临床场景,共收集267份回答。多数场景下各专科均倾向放疗联合全身治疗,但肿瘤内科和临床肿瘤科更常推荐单纯BRAF/MEK抑制剂或双药免疫检查点抑制剂,推荐因专科而异。

要点

  • 多数无症状黑色素瘤脑转移场景下,各专科专家均倾向放疗联合全身治疗。
  • BRAF突变阳性且1-3个均小于2cm脑转移时,51%肿瘤内科医生推荐单纯BRAF/MEK抑制剂。
  • 3个脑转移中至少1个大于2cm时,除肿瘤内科和放射肿瘤科对BRAF阴性推荐放疗外,各组均推荐 upfront 手术。

核心结论

  • 在多数涉及无症状黑色素瘤脑转移的临床场景中,专家推荐放疗联合全身治疗。
  • 推荐因专科显著不同,肿瘤内科和临床肿瘤科更常推荐单纯双药全身治疗用于最多9个小于2cm的BRAF阴性脑转移。

研究设计与样本

  • 国际调查,向肿瘤内科、临床肿瘤科、放射肿瘤科和神经外科专家呈现18个无症状BRAF突变阳性或阴性黑色素瘤脑转移特定临床场景。
  • 共收集267份回答,回答分组后使用Fisher精确检验比较。

主要发现

  • 多数黑色素瘤脑转移场景下,无论专科,调查受访者均倾向放疗联合全身治疗。
  • BRAF突变阳性脑转移患者中,肿瘤内科和临床肿瘤科较放射肿瘤科和神经外科显著更常推荐单纯BRAF/MEK抑制剂而不加放疗,包括多数肿瘤内科医生(51%)对1-3个均小于2cm脑转移的推荐。
  • BRAF阴性脑转移中,肿瘤内科和临床肿瘤科更常推荐单纯单药或双药免疫检查点抑制剂,双药免疫检查点抑制剂单用是肿瘤内科或临床肿瘤科对小于2cm脑转移最常见的推荐。
  • 3个脑转移中至少1个大于2cm时,所有组均推荐 upfront 手术,例外是肿瘤内科和放射肿瘤科对BRAF阴性脑转移推荐放疗。

关键数值与推荐

  • 肿瘤内科医生中51%对1-3个均小于2cm的BRAF突变阳性黑色素瘤脑转移推荐单纯BRAF/MEK抑制剂。
  • 肿瘤内科和临床肿瘤科更常推荐单纯双药全身治疗用于最多9个小于2cm的BRAF阴性黑色素瘤脑转移。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radiotherapy (RT) and surgery (Sx) are effective in treating brain metastases. However, immune checkpoint inhibitors (ICI) have shown activity against asymptomatic melanoma brain metastases (MBM). BRAF/MEK inhibitors can be used to treat BRAF V600 mutation positive (BRAF+) MBM. METHOD: We conducted an international survey among experts from medical oncology (MO), clinical oncology (CO), radiation oncology (RO), and neurosurgery (NS) about treatment recommendations for patients with asymptomatic BRAF+ or BRAF mutation negative (BRAF-) MBM. Eighteen specific clinical scenarios were presented and a total of 267 responses were collected. Answers were grouped and compared using Fisher's exact test. RESULTS: In most MBM scenarios, survey respondents, regardless of specialty, favored RT in addition to systemic therapy. However, for patients with BRAF+ MBM, MO and CO were significantly more likely than RO and NS to recommend BRAF/MEK inhibitors alone, without the addition of RT, including the majority of MO (51%) for patients with 1-3 MBM, all <2 cm. Likewise, for BRAF- MBM, MO and CO more commonly recommended single or dual agent ICI only and dual agent ICI therapy alone was the most common recommendation from MO or CO for MBM <2 cm. When at least 1 of 3 MBM (BRAF+ or BRAF-) was >2 cm, upfront Sx was recommended by all groups with the exception that MO and RO recommended RT for BRAF- MBM. CONCLUSIONS: In most clinical settings involving asymptomatic MBM, experts recommended RT in addition to systemic therapy. However, recommendations varied significantly according to specialty, with MO and CO more commonly recommending dual systemic therapy alone for up to 9 BRAF- MBM <2 cm.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Jablonska PA, Fong CH, Kruser T, et al. Recommended first-line management of brain metastases from melanoma: A multicenter survey of clinical practice. Radiother Oncol. 2022. PMID: 35121033. doi:10.1016/j.radonc.2022.01.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。